美国COVID-19疫苗接种第一年免疫实践咨询委员会(ACIP)使用获益-风险评估框架的总结
为支持ACIP的COVID-19疫苗政策决策,作者开发了直接比较个体接种获益(如预防COVID-19相关住院)与疫苗风险的获益-风险评估框架,该框架始于2021年4月发现Janssen COVID-19疫苗接种后血栓伴血小板减少综合征(TTS)。在美国COVID-19疫苗接种第一年(2020年12月至2021年12月),该框架用于为七项ACIP政策决策提供信息。
要点
- 获益-风险评估框架直接比较个体接种获益与疫苗风险,用于ACIP政策决策。
- 该框架起源于2021年4月发现Janssen COVID-19疫苗接种后TTS。
- 2020年12月至2021年12月期间,该框架用于为七项ACIP政策决策提供信息。
核心结论
- 该框架允许快速、直接地比较接种的获益与潜在危害,可能有助于为其他疫苗政策决策提供信息。
- 评估是决策的有用工具,但需要可靠和精细的数据来分层分析并适当关注特定不良事件风险最高的人群。
- 需要对数据输入参数进行仔细决策;在数据有限或不确定时使用敏感性分析;随时间调整方法以确保评估保持相关并适用于所考虑的政策问题。
研究设计与样本
- 作者开发了获益-风险评估框架,直接比较COVID-19疫苗接种对个体的估计获益与COVID-19疫苗相关风险。
主要发现
- 该评估框架起源于2021年4月发现Janssen COVID-19疫苗接种后血栓伴血小板减少综合征(TTS)。
- 该框架被调整用于后续政策决策,包括mRNA和Janssen COVID-19疫苗接种后分别发生的心肌炎和吉兰-巴雷综合征(GBS)不良事件、将COVID-19疫苗批准或授权扩大到新年龄组以及使用加强针。
- 在美国COVID-19疫苗接种第一年(2020年12月至2021年12月),作者使用该获益-风险评估框架为七项不同的ACIP政策决策提供信息。
临床怎么用
- 原文未据此给出推荐。
局限性
- 评估需要可靠和精细的数据来分层分析并适当关注特定不良事件风险最高的人群。
- 需要对数据输入参数进行仔细决策。
- 在数据有限或不确定时使用敏感性分析。
- 随时间调整方法以确保评估保持相关并适用于所考虑的政策问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To inform Advisory Committee for Immunization Practices (ACIP) COVID-19 vaccine policy decisions, we developed a benefit-risk assessment framework that directly compared the estimated benefits of COVID-19 vaccination to individuals (e.g., prevention of COVID-19-associated hospitalization) with risks associated with COVID-19 vaccines. This assessment framework originated following the identification of thrombosis with thrombocytopenia syndrome (TTS) after Janssen COVID-19 vaccination in April 2021. We adapted the benefit-risk assessment framework for use in subsequent policy decisions, including the adverse events of myocarditis and Guillain-Barre syndrome (GBS) following mRNA and Janssen COVID-19 vaccination respectively, expansion of COVID-19 vaccine approvals or authorizations to new age groups, and use of booster doses. Over the first year of COVID-19 vaccine administration in the United States (December 2020-December 2021), we used the benefit-risk assessment framework to inform seven different ACIP policy decisions. This framework allowed for rapid and direct comparison of the benefits and potential harms of vaccination, which may be helpful in informing other vaccine policy decisions. The assessments were a useful tool for decision-making but required reliable and granular data to stratify analyses and appropriately focus on populations most at risk for a specific adverse event. Additionally, careful decision-making was needed on parameters for data inputs. Sensitivity analyses were used where data were limited or uncertain; adjustments in the methodology were made over time to ensure the assessments remained relevant and applicable to the policy questions under consideration.
引用
- Wallace M, Rosenblum HG, Moulia DL, et al. A summary of the Advisory Committee for Immunization Practices (ACIP) use of a benefit-risk assessment framework during the first year of COVID-19 vaccine administration in the United States. Vaccine. 2023. PMID: 37527956. doi:10.1016/j.vaccine.2023.07.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。